ZS Pharma Targeted By Diversity-Seeking Actelion
This article was originally published in Scrip
Actelion Pharmaceuticals confirmed on Sept. 10 that it is considering a purchase of hyperkalemia drug developer ZS Pharma, which would diversify the Swiss company's portfolio beyond its dominant disease area of pulmonary arterial hypertension (PAH) and meet Actelion's goal of acquiring assets in new areas with high unmet needs.
You may also be interested in...
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.